Published in J Gen Virol on January 01, 2008
Seroprevalence of 34 human papillomavirus types in the German general population. PLoS Pathog (2008) 1.44
Age-specific seroprevalences of merkel cell polyomavirus, human polyomaviruses 6, 7, and 9, and trichodysplasia spinulosa-associated polyomavirus. Clin Vaccine Immunol (2013) 1.36
The use of human papillomavirus seroepidemiology to inform vaccine policy. Sex Transm Dis (2009) 1.14
Disassembly and reassembly of human papillomavirus virus-like particles produces more virion-like antibody reactivity. Virol J (2012) 1.04
Seroprevalence of 8 oncogenic human papillomavirus genotypes and acquired immunity against reinfection. J Infect Dis (2014) 0.94
Analysis of modified human papillomavirus type 16 L1 capsomeres: the ability to assemble into larger particles correlates with higher immunogenicity. J Virol (2009) 0.89
Binding and neutralization characteristics of a panel of monoclonal antibodies to human papillomavirus 58. J Gen Virol (2010) 0.89
Natural immune responses against eight oncogenic human papillomaviruses in the ASCUS-LSIL Triage Study. Int J Cancer (2013) 0.89
Guidelines of the Italian Society for Virology on HPV testing and vaccination for cervical cancer prevention. Infect Agent Cancer (2008) 0.89
Development of neutralizing monoclonal antibodies for oncogenic human papillomavirus types 31, 33, 45, 52, and 58. Clin Vaccine Immunol (2014) 0.88
Identification of B-cell epitopes on virus-like particles of cutaneous alpha-human papillomaviruses. J Virol (2009) 0.87
Glutathione S-transferase L1 multiplex serology as a measure of cumulative infection with human papillomavirus. BMC Infect Dis (2014) 0.87
Identification of species-specific and cross-reactive epitopes in human polyomavirus capsids using monoclonal antibodies. J Gen Virol (2009) 0.87
Identification of neutralizing conformational epitopes on the human papillomavirus type 31 major capsid protein and functional implications. Protein Sci (2009) 0.86
Structural comparison of four different antibodies interacting with human papillomavirus 16 and mechanisms of neutralization. Virology (2015) 0.85
Sound efficacy of prophylactic HPV vaccination: Basics and implications. Oncoimmunology (2012) 0.83
A chimeric 18L1-45RG1 virus-like particle vaccine cross-protects against oncogenic alpha-7 human papillomavirus types. PLoS One (2015) 0.81
Papillomavirus capsid proteins mutually impact structure. Virology (2011) 0.81
Cross-neutralizing antibodies elicited by the Cervarix® human papillomavirus vaccine display a range of Alpha-9 inter-type specificities. Vaccine (2014) 0.81
Amino acid sequence diversity of the major human papillomavirus capsid protein: implications for current and next generation vaccines. Infect Genet Evol (2013) 0.80
The choice of resin-bound ligand affects the structure and immunogenicity of column-purified human papillomavirus type 16 virus-like particles. PLoS One (2012) 0.79
Study of infectious virus production from HPV18/16 capsid chimeras. Virology (2010) 0.78
The U4 Antibody Epitope on Human Papillomavirus 16 Identified by Cryo-electron Microscopy. J Virol (2015) 0.78
Pre-clinical immunogenicity of human papillomavirus alpha-7 and alpha-9 major capsid proteins. Vaccine (2014) 0.77
The concentration of carbon source in the medium affects the quality of virus-like particles of human papillomavirus type 16 produced in Saccharomyces cerevisiae. PLoS One (2014) 0.76
Human papillomavirus DNA positivity and seropositivity in rural Chinese men and women: a population-based cross-sectional study. Sci Rep (2016) 0.75
Clinical and epidemiological correlates of antibody response to human papillomaviruses (HPVs) as measured by a novel ELISA based on denatured recombinant HPV16 late (L) and early (E) antigens. Infect Agent Cancer (2008) 0.75
Generation and characterization of neutralizing monoclonal antibodies against baculo-expressed HPV 16 VLPs. Eur J Microbiol Immunol (Bp) (2014) 0.75
Case-control study of human papillomavirus and oropharyngeal cancer. N Engl J Med (2007) 16.39
Human papillomavirus and oral cancer: the International Agency for Research on Cancer multicenter study. J Natl Cancer Inst (2003) 6.28
The structural basis for cap binding by influenza virus polymerase subunit PB2. Nat Struct Mol Biol (2008) 4.33
A novel algorithm for reliable detection of human papillomavirus in paraffin embedded head and neck cancer specimen. Int J Cancer (2007) 4.29
Multiplex human papillomavirus serology based on in situ-purified glutathione s-transferase fusion proteins. Clin Chem (2005) 4.18
Bead-based multiplex genotyping of human papillomaviruses. J Clin Microbiol (2006) 3.13
Cell-wall recovery after irreversible deformation of wood. Nat Mater (2003) 3.09
Suppression of non-specific binding in serological Luminex assays. J Immunol Methods (2005) 2.96
Evaluation of human papillomavirus antibodies and risk of subsequent head and neck cancer. J Clin Oncol (2013) 2.87
Carrageenan is a potent inhibitor of papillomavirus infection. PLoS Pathog (2006) 2.65
JAK2-V617F mutation in a patient with Philadelphia-chromosome-positive chronic myeloid leukaemia. Lancet Oncol (2007) 2.44
Human papillomavirus infection and incidence of squamous cell and basal cell carcinomas of the skin. J Natl Cancer Inst (2006) 2.40
A protective and broadly cross-neutralizing epitope of human papillomavirus L2. J Virol (2007) 2.36
Cross-neutralization of cutaneous and mucosal Papillomavirus types with anti-sera to the amino terminus of L2. Virology (2005) 2.31
Further evidence that papillomavirus capsids exist in two distinct conformations. J Virol (2003) 2.02
Helicobacter pylori protein-specific antibodies and risk of colorectal cancer. Cancer Epidemiol Biomarkers Prev (2013) 2.01
HPV antibody detection by ELISA with capsid protein L1 fused to glutathione S-transferase. J Virol Methods (2002) 1.97
Synthetic double-stranded RNAs are adjuvants for the induction of T helper 1 and humoral immune responses to human papillomavirus in rhesus macaques. PLoS Pathog (2009) 1.92
Homogeneous amplification of genital human alpha papillomaviruses by PCR using novel broad-spectrum GP5+ and GP6+ primers. J Clin Microbiol (2008) 1.90
Oxidation-responsive polymeric vesicles. Nat Mater (2004) 1.82
Crystal structures of four types of human papillomavirus L1 capsid proteins: understanding the specificity of neutralizing monoclonal antibodies. J Biol Chem (2007) 1.77
Biomarkers of HPV in head and neck squamous cell carcinoma. Cancer Res (2012) 1.76
Human papillomaviruses bind a basal extracellular matrix component secreted by keratinocytes which is distinct from a membrane-associated receptor. Virology (2005) 1.73
Protection of rabbits against challenge with rabbit papillomaviruses by immunization with the N terminus of human papillomavirus type 16 minor capsid antigen L2. J Virol (2007) 1.70
Keratinocyte-secreted laminin 5 can function as a transient receptor for human papillomaviruses by binding virions and transferring them to adjacent cells. J Virol (2006) 1.67
Residues in the HIV-1 capsid assembly inhibitor binding site are essential for maintaining the assembly-competent quaternary structure of the capsid protein. J Biol Chem (2008) 1.61
RIM-binding protein, a central part of the active zone, is essential for neurotransmitter release. Science (2011) 1.59
High-risk HPV types and head and neck cancer. Int J Cancer (2014) 1.56
Evaluation of antibodies to human papillomavirus as prognostic markers in cervical cancer patients. Gynecol Oncol (2002) 1.56
Low human papillomavirus prevalence in head and neck cancer: results from two large case-control studies in high-incidence regions. Int J Epidemiol (2011) 1.55
Abundance of multiple high-risk human papillomavirus (HPV) infections found in cervical cells analyzed by use of an ultrasensitive HPV genotyping assay. J Clin Microbiol (2009) 1.55
Human papillomavirus-16 is the predominant type etiologically involved in penile squamous cell carcinoma. J Clin Oncol (2007) 1.53
Immunological responses in women with human papillomavirus type 16 (HPV-16)-associated anogenital intraepithelial neoplasia induced by heterologous prime-boost HPV-16 oncogene vaccination. Clin Cancer Res (2004) 1.51
Viral RNA patterns and high viral load reliably define oropharynx carcinomas with active HPV16 involvement. Cancer Res (2012) 1.49
High-throughput detection and multiplex identification of cell contaminations. Nucleic Acids Res (2009) 1.49
Protective immunity to rabbit oral and cutaneous papillomaviruses by immunization with short peptides of L2, the minor capsid protein. J Virol (2002) 1.48
Risk factors for anal cancer in persons infected with HIV: a nested case-control study in the Swiss HIV Cohort Study. Am J Epidemiol (2013) 1.48
Insulators, not Polycomb response elements, are required for long-range interactions between Polycomb targets in Drosophila melanogaster. Mol Cell Biol (2010) 1.47
High-throughput SNP-based authentication of human cell lines. Int J Cancer (2012) 1.46
Serologic response to oncogenic human papillomavirus types in male and female university students in Busan, South Korea. Cancer Epidemiol Biomarkers Prev (2007) 1.45
Reelin deficiency and displacement of mature neurons, but not neurogenesis, underlie the formation of granule cell dispersion in the epileptic hippocampus. J Neurosci (2006) 1.45
In vitro versus in vivo cellulose microfibrils from plant primary wall synthases: structural differences. J Biol Chem (2002) 1.44
Neuromyelitis optica following human papillomavirus vaccination. Neurology (2012) 1.44
Seroprevalence of 34 human papillomavirus types in the German general population. PLoS Pathog (2008) 1.44
Type-specific antiviral antibodies to genital human papillomavirus types in mothers and newborns. Reprod Sci (2007) 1.43
Worldwide human papillomavirus genotype attribution in over 2000 cases of intraepithelial and invasive lesions of the vulva. Eur J Cancer (2013) 1.42
IL-13Ralpha2 is a glioma-restricted receptor for interleukin-13. Neoplasia (2002) 1.42
Human papillomavirus DNA prevalence and type distribution in anal carcinomas worldwide. Int J Cancer (2014) 1.40
Human papillomavirus seropositivity and risks of head and neck cancer. Int J Cancer (2007) 1.39
Recognition of 2'-O-methylated 3'-end of piRNA by the PAZ domain of a Piwi protein. Structure (2011) 1.37
Kinetics of in vitro adsorption and entry of papillomavirus virions. Virology (2004) 1.37
Identification of two cross-neutralizing linear epitopes within the L1 major capsid protein of human papillomaviruses. J Virol (2002) 1.35
The significance of direct sunlight and polarized skylight in the ant's celestial system of navigation. Proc Natl Acad Sci U S A (2006) 1.35
Helicobacter pylori infection and gastric cancer risk: evaluation of 15 H. pylori proteins determined by novel multiplex serology. Cancer Res (2009) 1.33
Propagation, infection, and neutralization of authentic HPV16 virus. Virology (2004) 1.32
Multicenter study of the association between betapapillomavirus infection and cutaneous squamous cell carcinoma. Cancer Res (2010) 1.30
Human papillomavirus infection in Ulaanbaatar, Mongolia: a population-based study. Cancer Epidemiol Biomarkers Prev (2008) 1.29
Human papillomavirus infections and upper aero-digestive tract cancers: the ARCAGE study. J Natl Cancer Inst (2013) 1.29
Helicobacter pylori multiplex serology. Helicobacter (2009) 1.29
Identification of a human papillomavirus type 16-specific epitope on the C-terminal arm of the major capsid protein L1. J Virol (2003) 1.27
Nuclear translocation of papillomavirus minor capsid protein L2 requires Hsc70. J Virol (2004) 1.27
Complex etiology underlies risk and survival in head and neck cancer human papillomavirus, tobacco, and alcohol: a case for multifactor disease. J Oncol (2012) 1.27
Race, African ancestry, and Helicobacter pylori infection in a low-income United States population. Cancer Epidemiol Biomarkers Prev (2011) 1.26
Human papillomavirus type 16 and TP53 mutation in oral cancer: matched analysis of the IARC multicenter study. Cancer Res (2004) 1.25
A papillomavirus-like particle (VLP) vaccine displaying HPV16 L2 epitopes induces cross-neutralizing antibodies to HPV11. Vaccine (2006) 1.25
Immunological and clinical responses in women with vulval intraepithelial neoplasia vaccinated with a vaccinia virus encoding human papillomavirus 16/18 oncoproteins. Cancer Res (2003) 1.24
A small molecule antagonist of the alpha(v)beta3 integrin suppresses MDA-MB-435 skeletal metastasis. Clin Exp Metastasis (2004) 1.23
Pathogenic role of the eight probably/possibly carcinogenic HPV types 26, 53, 66, 67, 68, 70, 73 and 82 in cervical cancer. J Pathol (2014) 1.23
Quantitative RT-PCR assay for HPV infection in cultured cells. J Virol Methods (2003) 1.23
A prospective pilot study of antibodies against human papillomaviruses and cutaneous squamous cell carcinoma nested in the Oxford component of the European Prospective Investigation into Cancer and Nutrition. Int J Cancer (2007) 1.22
Versatile biosynthetic engineering of sialic acid in living cells using synthetic sialic acid analogues. J Biol Chem (2001) 1.22
Prediction of left ventricular remodeling and analysis of infarct resorption in patients with reperfused myocardial infarcts by using contrast-enhanced MR imaging. Radiology (2007) 1.21
The Mcp element mediates stable long-range chromosome-chromosome interactions in Drosophila. Mol Biol Cell (2006) 1.21
Genus beta human papillomaviruses and incidence of basal cell and squamous cell carcinomas of skin: population based case-control study. BMJ (2010) 1.18